Literature DB >> 23067326

Risks and adverse outcomes associated with emergency-release red blood cell transfusion.

Sudhanshu B Mulay1, Elizabeth A Jaben, Pamela Johnson, Karafa Badjie, James R Stubbs.   

Abstract

BACKGROUND: Group O red blood cell (RBC) units are used for emergency transfusions and are often uncrossmatched when transfused. We sought to determine the risk of alloimmunization and identify acute adverse outcomes of this practice. STUDY DESIGN AND METHODS: The transfusion medicine database was searched for emergency-release transfusion (ERT) episodes from January 2006 through December 2010. The data collected included age and sex of the recipient, blood bank history, survival after the ERT episode, antibody screen results, antibody identifications, and compatibility of released units.
RESULTS: A total of 1444 ERT episodes took place involving 1407 patients. A total of 4144 RBC units were released. Of the 129 positive antibody screens, 34 had no antibody on further work-up, 14 had autoantibodies, 48 had a single antibody specificity, and 25 had multiple antibody specificities. Seven patients developed an antibody that could be attributed to the ERT episode, and 15 patients developed an antibody after ERT and additional RBC transfusions. There were 32 reported suspected transfusion reactions. No acute hemolytic transfusion reactions were reported. Seven patients were given a total of 10 incompatible RBC units. Of these patients, one developed a delayed serologic transfusion reaction. The rate of alloimmunization attributable to ERT was 3%. Overall, the rate of incompatible transfusion was less than 0.3% and the rate of a delayed hemolytic transfusion reaction was approximately 0.02%.
CONCLUSION: There is minimal risk associated with the release of emergency uncrossmatched blood in the setting of an acutely bleeding patient. [Correction statement added after online publication 15-Oct-2012: the number of patients with autoantibodies, single antibody specificity and multiple antibody specificity has been update.].
© 2012 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23067326     DOI: 10.1111/j.1537-2995.2012.03922.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Unmatched Type O RhD+ Red Blood Cells in Multiple Injured Patients.

Authors:  Sabine Flommersfeld; Carsten Mand; Christian A Kühne; Gregor Bein; Steffen Ruchholtz; Ulrich J Sachs
Journal:  Transfus Med Hemother       Date:  2018-03-07       Impact factor: 3.747

Review 2.  Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.

Authors:  Guido Lancman; Suzanne Arinsburg; Jeffrey Jhang; Hearn Jay Cho; Sundar Jagannath; Deepu Madduri; Samir Parekh; Joshua Richter; Ajai Chari
Journal:  Front Immunol       Date:  2018-11-15       Impact factor: 7.561

3.  Safety of Uncrossmatched ABO-Compatible RBCs in Alloimmunized Patients with Bleeding: Data from Two Decades: Results of a Systematic Analysis in 6,109 Patients.

Authors:  Frauke Ringel; Helge Schoenfeld; Said El Bali; Jalid Sehouli; Claudia Spies; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2021-12-08       Impact factor: 4.040

4.  Efficacy of Uncross-Matched Type O Packed Red Blood Cell Transfusion to Traumatic Shock Patients: a Propensity Score Match Study.

Authors:  Byung Hee Kang; Donghwan Choi; Jayun Cho; Junsik Kwon; Yo Huh; Jonghwan Moon; Younghwan Kim; Kyoungwon Jung; John Cook Jong Lee
Journal:  J Korean Med Sci       Date:  2017-12       Impact factor: 2.153

5.  Tranexamic acid reduces blood loss in intertrochanteric fractures: A meta-analysis from randomized controlled trials.

Authors:  Weidong Wang; Jincong Yu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

6.  Utilisation of emergency blood in a cohort of South African emergency centres with no direct access to a blood bank.

Authors:  David Morris; Daniël van Hoving; Melanie Stander; Stevan Bruijns
Journal:  Afr J Emerg Med       Date:  2019-02-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.